WO2014147119A1 - Silybin for the treatment of metabolic oxidative alterations in patients with non-alcoholic steatohepatitis (nash) - Google Patents
Silybin for the treatment of metabolic oxidative alterations in patients with non-alcoholic steatohepatitis (nash) Download PDFInfo
- Publication number
- WO2014147119A1 WO2014147119A1 PCT/EP2014/055499 EP2014055499W WO2014147119A1 WO 2014147119 A1 WO2014147119 A1 WO 2014147119A1 EP 2014055499 W EP2014055499 W EP 2014055499W WO 2014147119 A1 WO2014147119 A1 WO 2014147119A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patients
- treatment
- group
- silybin
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02K—DYNAMO-ELECTRIC MACHINES
- H02K41/00—Propulsion systems in which a rigid body is moved along a path due to dynamo-electric interaction between the body and a magnetic field travelling along the path
- H02K41/02—Linear motors; Sectional motors
- H02K41/03—Synchronous motors; Motors moving step by step; Reluctance motors
Definitions
- the present invention relates to a composition comprising silybin for the treatment of metabolic oxidative alterations in non-alcoholic steatohepatitis (NASH).
- NASH non-alcoholic steatohepatitis
- Oxidative stress, lipid peroxidation, antioxidant therapy, these terms are very common in the literature and in everyday clinical practice in recent years. In fact, in the pathogenesis of various diseases, including cancer, considerable emphasis is often given to the formation of free radicals and their entrapment by antioxidant substances.
- oxidative stress markers considered expression of pathology of various organs and systems
- the increase of products from lipid peroxidation plays a prominent role.
- Lipid peroxidation markers in the circulation are present in many pathological conditions as an expression of peroxidation of cell membranes.
- various diseases surely the metabolic syndrome, but also the chronic liver disease and the advanced stages of many cancers, represent pathognomonic situations of chronic diseases, in which the oxidative stress plays a key role.
- Non-alcoholic steatohepatitis is the hepatic manifestation of metabolic syndrome.
- Non-alcoholic steatohepatitis is a type of chronic damage to the liver belonging to metabolic diseases and represents the degenerative inflammatory progression of the non-alcoholic fatty liver disease (NAFLD).
- NASH non-alcoholic hepatic steatosis to steatohepatitis
- NAFLD non-alcoholic fatty liver disease
- Object of the present invention is to provide a treatment of the metabolic syndrome, when associated to NASH
- the inventors of the present invention have identified among the patients with metabolic syndrome, when associated to NASH, a group of patients presenting a lipidomic profile alteration associated with high values of TBARS in serum, and have surprisingly discovered that treatment with a composition including silybin allows normalization of said lipidomic profile, thus having effects in the treatment of non-alcoholic steatohepatitis.
- the invention thus relates to a composition for use in the treatment of metabolic oxidative alterations in patients with non-alcoholic steatohepatitis (NASH), wherein said composition comprises silybin, and wherein the treatment is administered to patients having an altered lipidomic profile.
- NASH non-alcoholic steatohepatitis
- altered lipidomic profile when used, it is meant the lipidomic profile of a patient with metabolic syndrome, preferably also with NASH, who is positive to the TBARS assay, who specifically show high values of TBARS in the TBARS assay ((2-ThioBarbituric Acid Reactive Substances (TBARS)).
- the TBARS assay measures in a serum sample of a patient the TBARS, i.e. the by-products generated by a process of lipid peroxidation, through the use of barbituric acid (Armstrong, D., and Browne, R. The analysis of free radicals, lipid peroxides, antioxidant enzymes and compounds to oxidative stress as applied to the clinical chemistry laboratory.
- the inventors of the present invention have therefore identified a specific group of patients with the metabolic syndrome and with also NASH, who have an alteration of serum lipidomics and who are responsive to treatment with a composition comprising silybin.
- the group of patients identified by the inventors in the group of patients with metabolic syndrome with also NASH have a lipidomic profile associated with altered lipid peroxidation (high values of TBARS) that distinguishes it from the group of patients with metabolic syndrome with also NASH, who, in basic conditions, do not show high levels of circulating lipid peroxidation markers (TBARS).
- the two groups of patients are in no way overlapping on the basis of the values of TBARS determined by the TBARS assay, as will be evident from the experimental section below.
- the group of patients of the invention Upon completion of the treatment with the composition including silybin, the group of patients of the invention showed a normalization of the serum lipidomic profile, with a corresponding lowering of the values of TBARS in the TBARS assay, confirming the treatment of oxidative stress typical of NASH pathology.
- Figure 1 includes graphs of mass spectroscopy of a pool of serum samples of the control group (CTR) (a)), the first group of NASH patients at time zero (TO, Group 1 ) (b)) and the second group of NASH patients at time zero (TO, Gruppo 2) (c)).
- Figure 2 includes the graphs of mass spectroscopy of a pool of serum samples of the first group of NASH patients after 12 months of treatment (T12) with the composition of the invention (Group 1 ) (b)) and the second group of NASH patients after 12 months of treatment (T12) with the composition of the invention (Group 2) (c)).
- the invention therefore relates to a composition for use in the treatment of metabolic oxidative alterations in non-alcoholic steatohepatitis (NASH), and wherein said composition comprises silybin, and wherein the treatment is administered to patients having an altered lipidomic profile.
- NASH non-alcoholic steatohepatitis
- the group of patients having the "altered lipid profile" show an high TBARS value in TBARS assay with respect to healthy subjects.
- the TBARS assay detects the substances reactive to barbituric acid, which are formed as by-products of lipid peroxidation. Therefore, TBARS levels represent a marker of lipid peroxidation.
- a patient having the metabolic syndrome with also NASH, who is positive to the TBARS assay, show high values of TBARS in the TBARS assay, i.e. a large number of lipidic peroxidation by-products of the cell membranes is present in the serum of the patient.
- the inventors of the present invention have therefore identified a sub-group of patients with the metabolic syndrome with also NASH, who have an alteration of lipidomics and who are responsive to treatment with a composition comprising silybin.
- the composition of the invention comprises silybin, preferably complexed with phosphatidylcholine.
- Silybin used in the invention can be in the form of an extract of Silybum marianum, i.e. Milk thistle. It is known that extracts of Milk thistle can be titrated with silybin or silymarin, in the invention all these extracts can be used. Extracts of Milk thistle are preferred, titrated with silybin in the range of 20 to 90%, more preferably of 30 to 70%. Even more preferably, the composition of the invention comprises an extract of Silibum marianum titrated with 33% silybin.
- the composition comprises preferably vitamin E.
- the composition of the invention includes an extract of Milk thistle, complexed with phosphatidylcholine and vitamin E acetate.
- composition of the invention comprises also excipients suitable for the preparation of a pharmaceutical formulation.
- the daily dose of silybin is in the range of 150 to 300 mg/day, being even more preferable a dose of about 200 mg/day of silybin.
- the group of patients with the metabolic syndrome with also NASH, and identified in the treatment according to the invention have therefore an altered lipidomic profile, which are normalized with the composition of the invention, as will be evident from the experimental part that follows.
- composition so obtained was administered to the patients in the form of sachets of powder composition.
- Table 2 also shows the values of TBARS measured in patients not only at time zero (TO), but even after 12 months of treatment (T12).
- TBARS substances reactive to thiobarbituric acid.
- Table 3 shows the average of the levels of TBARS measured at time zero (TO) and after 12 months of treatment for groups 1 and 2 of the patients and the average of the values of TBARS in the control group (CTR).
- TO time zero
- CTR control group
- the first group of patients (Group 1 ) in basal conditions showed a value of substances reactive to thiobarbituric acid (TBARS) lower compared to the control values.
- TBARS levels increased immediately, but these values returned to normal values at the end of the treatment, after 12 months.
- the second group (Group 2) showed a very high value of TBARS in basal conditions, compared to the average value of the control.
- the treatment with the composition of the invention significantly reduced the average level of TBARS (p ⁇ 0.01 ).
- group 1 had low values at time 0 and the second on the contrary had high values (compared to the control group of healthy subjects), getting closer to the values of the control group after 12 months of treatment.
- Table 4 Average values of metabolic parameters for the two groups of patients at basal condition (TO) and after 12 months of treatment with the composition of the invention (T12).
- Group 1 Group 2
- composition of the invention therefore reduced the body mass index, insulin and insulin resistance (HOMA) of the sole Group 2, determining thus a treatment of the metabolic syndrome and NASH only for this group of patients.
- HOMA body mass index
- Example 3 The use of the composition of the invention therefore reduced the body mass index, insulin and insulin resistance (HOMA) of the sole Group 2, determining thus a treatment of the metabolic syndrome and NASH only for this group of patients.
- Example 2 The 20 patients with metabolic syndrome and non-alcoholic steatohepatitis (NASH), divided into two groups as shown in Example 2 were treated with the composition of the invention for 12 months at a dose of 4 sachets/day.
- NASH non-alcoholic steatohepatitis
- lipidomics analysis was performed by MALDI-TOF mass spectroscopy. Lipidomic species studied in the analysis, corresponding to the main peaks were:
- Lyso lysophosphatidylcholine, which can have different combinations of fatty acids with varying length and saturation bound at position C-1 .
- lyso PC 16:0 lysophosphatidylcholine with palmitic acid
- SM sphingomyelin PC: phosphatidylcholine, which can have different combinations of fatty acids with varying length and saturation bound at positions C-1 and C2.
- PC 16:0/18:2 phosphatidylcholine which has a chain of palmitic acid in position C- 1 and a chain of linoleic acid in position C2
- PC 16:0/18:1 phosphatidylcholine which has a chain of palmitic acid in position C- 1 and a chain of oleic acid in position C2
- PC 18:1 /18:2 phosphatidylcholine which has a chain of oleic acid in position C-1 and a chain of linoleic acid in position C2
- PC 18:0/18:2 phosphatidylcholine which has a chain of stearic acid in position C- 1 and a chain of linoleic acid in position C2
- PC 18:1 /18:1 phosphatidylcholine which has a chain of oleic acid in position C-1 and a chain of oleic acid in position C2
- PC 18:2/18:2 phosphatidylcholine which has a chain of oleic acid in position C-1 and a chain of linoleic acid in position C2
- PC 18:0/18:2 phosphatidylcholine which has a chain of stearic acid in position C- 1 and a chain of linoleic acid in position C2
- PC 18:1 /20:4 phosphatidylcholine which has a chain of oleic acid in position C-1 and a chain of arachidonic acid in position C2
- PC 18:0/20:4 phosphatidylcholine which has a chain of stearic acid in position C- 1 and a chain of arachidonic acid in position C2
- PC 18:0/20:3 phosphatidylcholine which has a chain of stearic acid in position C- 1 and a chain of homo-g-linolenic acid in position C2.
- a pool of the patients' serum was then made, i.e. a pool of the serum of patients belonging to group 1 and a pool of the serum of patients in group 2. Also a pool of the serum was made for the subjects belonging to the control group.
- the pools were collected and analyzed before treatment and after the treatment. For each pool graphs were drafted of MALDI-TOF mass spectrometry of organic extracts obtained from the sera of the patients themselves.
- Figure 1 shows the following graphs: spectrogram a. reports the lipidomic profile of the pool of the normal subjects (control group), the spectrogram b. shows the lipidomic profile of the pool of patients belonging to group 1 and the spectrogram c. shows the lipidomic profile of the pool of patients belonging to group 2 (at time As it is evident from Figure 1 , both patients of Group 1 and Group 2 had a lipidic profile different from the profile of the control group. Specifically, all tested species were present in the serum of patients in amounts lower than the amounts of the control subjects (the experiments were repeated three times).
- lipidomic profile in Group 2 at T12 resulted more similar to that one of the control group, thus demonstrating that a normalization had occurred for the lipidomic profile, as tested after the treatment with the composition of the invention.
- lyso PC lysophosphatidylcholine
- PC phosphatidylcholine
- SM sphingomyelin
- Sphingomyelin has a high affinity for cholesterol, with which it binds at the cell membrane level.
- the treatment according to the invention catalyzes the release of free circulating sphingomyelin and cholesterol, through an increase in the lyso-phosphatidylcholine ratio, which has a "detergent-like" action on the membranes.
- lipid extraction and analysis of lipidomic profile with mass spectrometry were carried out several times for the pool of patients of group 1 , group 2, and the control group, thus obtaining results which could be superimposed to those reported above, thus confirming that the lipidomic profile of the patients in group 2 was normalized.
- the results obtained from the lipidomic analysis when added to the reductions in the insulinemia and insulin resistance (see Table 3 of Example 2), show that only for patients with metabolic syndrome and NASH of Group 2, the composition including silybin interfered with the cell intermediate metabolism concerning the oxidation of lipids, decreasing the oxidative stress typical of the metabolic syndrome and NASH, and, therefore, having the effects of the treatment on the same only for this specific group of patients.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Combustion & Propulsion (AREA)
- Electromagnetism (AREA)
- Power Engineering (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112015024181A BR112015024181A2 (en) | 2013-03-20 | 2014-03-19 | use of a composition comprising silybin |
DK14718921.1T DK2976075T3 (en) | 2013-03-20 | 2014-03-19 | SILYBIN FOR TREATMENT OF METABOLIC OXIDATIVE CHANGES IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) |
PL14718921T PL2976075T3 (en) | 2013-03-20 | 2014-03-19 | Silybin for the treatment of metabolic oxidative alterations in patients with non-alcoholic steatohepatitis (nash) |
EP14718921.1A EP2976075B1 (en) | 2013-03-20 | 2014-03-19 | Silybin for the treatment of metabolic oxidative alterations in patients with non-alcoholic steatohepatitis (nash) |
RU2015144870A RU2694896C2 (en) | 2013-03-20 | 2014-03-19 | Composition for treating metabolic oxidative changes in patients with non-alcoholic steatohepatitis (nash) |
ES14718921T ES2749192T3 (en) | 2013-03-20 | 2014-03-19 | Silybin for the treatment of metabolic oxidative disorders in patients with non-alcoholic steatohepatitis (NASH) |
MX2015013409A MX370252B (en) | 2013-03-20 | 2014-03-19 | Silybin for the treatment of metabolic oxidative alterations in patients with non-alcoholic steatohepatitis (nash). |
JP2016503648A JP2016515540A (en) | 2013-03-20 | 2014-03-19 | Composition for the treatment of metabolic oxidative changes in patients with non-alcoholic steatohepatitis (NASH) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000425A ITMI20130425A1 (en) | 2013-03-20 | 2013-03-20 | COMPOSITION FOR THE TREATMENT OF THE METABOLIC SYNDROME AND THE METABOLIC-OXIDATIVE ALTERATIONS IN PATIENTS WITH NON-ALCOHOLIC STEATOEPATITIS (NASH) |
ITMI2013A000425 | 2013-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014147119A1 true WO2014147119A1 (en) | 2014-09-25 |
Family
ID=48444504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/055499 WO2014147119A1 (en) | 2013-03-20 | 2014-03-19 | Silybin for the treatment of metabolic oxidative alterations in patients with non-alcoholic steatohepatitis (nash) |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2976075B1 (en) |
JP (1) | JP2016515540A (en) |
BR (1) | BR112015024181A2 (en) |
DK (1) | DK2976075T3 (en) |
ES (1) | ES2749192T3 (en) |
HU (1) | HUE045695T2 (en) |
IT (1) | ITMI20130425A1 (en) |
MX (1) | MX370252B (en) |
PL (1) | PL2976075T3 (en) |
PT (1) | PT2976075T (en) |
RU (1) | RU2694896C2 (en) |
WO (1) | WO2014147119A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3275457A4 (en) * | 2015-03-23 | 2018-02-21 | Tasly Pharmaceutical Group Co., Ltd. | Pharmaceutical composition containing silybin |
JP2018509428A (en) * | 2015-03-23 | 2018-04-05 | タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドTasly Pharmaceutical Group Co., Ltd. | Drug composition containing silybin |
CN108685899A (en) * | 2017-04-07 | 2018-10-23 | 澳门科技大学 | Flavanolignan is in the application for preparing the drug for treating autoimmune inflammatory diseases |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1513444A (en) * | 2003-07-11 | 2004-07-21 | 辽宁医联新药研究所 | Medicine for treating metaboic syndrome |
DE102004054133A1 (en) * | 2003-11-10 | 2005-06-09 | Naturprodukt Cz Spol. S.R.O., Praha - Vychod | Silymarin-based food supplement for improving diet and reducing the risk of diseases of civilization, e.g. diabetes, contains a standardized flavonolignan fraction from Marian thistle and a dried Yacon root preparation |
US20100239552A1 (en) * | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Combination Therapies for Treating Metabolic Disorders |
US20100255127A1 (en) * | 2007-11-21 | 2010-10-07 | Kracie Pharma, Ltd. | Aromatase inhibitor |
WO2013086323A2 (en) * | 2011-12-08 | 2013-06-13 | Metaproteomics, Llc | Supplemented oil compositions and methods for improved health |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1215291B (en) * | 1985-07-17 | 1990-01-31 | Inverni Della Beffa Spa | FLAVANOLIGNANI COMPLEXES WITH PHOSPHOLIPIDS, THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS. |
-
2013
- 2013-03-20 IT IT000425A patent/ITMI20130425A1/en unknown
-
2014
- 2014-03-19 EP EP14718921.1A patent/EP2976075B1/en active Active
- 2014-03-19 PT PT147189211T patent/PT2976075T/en unknown
- 2014-03-19 RU RU2015144870A patent/RU2694896C2/en active
- 2014-03-19 WO PCT/EP2014/055499 patent/WO2014147119A1/en active Application Filing
- 2014-03-19 ES ES14718921T patent/ES2749192T3/en active Active
- 2014-03-19 PL PL14718921T patent/PL2976075T3/en unknown
- 2014-03-19 DK DK14718921.1T patent/DK2976075T3/en active
- 2014-03-19 BR BR112015024181A patent/BR112015024181A2/en not_active Application Discontinuation
- 2014-03-19 HU HUE14718921A patent/HUE045695T2/en unknown
- 2014-03-19 JP JP2016503648A patent/JP2016515540A/en active Pending
- 2014-03-19 MX MX2015013409A patent/MX370252B/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1513444A (en) * | 2003-07-11 | 2004-07-21 | 辽宁医联新药研究所 | Medicine for treating metaboic syndrome |
DE102004054133A1 (en) * | 2003-11-10 | 2005-06-09 | Naturprodukt Cz Spol. S.R.O., Praha - Vychod | Silymarin-based food supplement for improving diet and reducing the risk of diseases of civilization, e.g. diabetes, contains a standardized flavonolignan fraction from Marian thistle and a dried Yacon root preparation |
US20100255127A1 (en) * | 2007-11-21 | 2010-10-07 | Kracie Pharma, Ltd. | Aromatase inhibitor |
US20100239552A1 (en) * | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Combination Therapies for Treating Metabolic Disorders |
WO2013086323A2 (en) * | 2011-12-08 | 2013-06-13 | Metaproteomics, Llc | Supplemented oil compositions and methods for improved health |
Non-Patent Citations (6)
Title |
---|
ARMSTRONG, D; BROWNE, R: "The analysis of free radicals, lipid peroxides, antioxidant enzymes and compounds to oxidative stress as applied to the clinical chemistry laboratory", FREE RADICALS IN DIAGNOSTIC MEDICINE, vol. 366, 1994, pages 43 - 58, XP008067574 |
FEDERICO ALESSANDRO ET AL: "The effect of a chronic treatment with silibinin on insulin-resistance and plasma markers of liver fibrosis in patients with chronic liver damage.", HEPATOLOGY, vol. 40, no. 4, Suppl. 1, October 2004 (2004-10-01), & 55TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-THE-STUDY-OF-LIVER-DISEASES (AASLD); BOSTON, MA, USA; OCTOBER 29 -NOVEMBER 02, 2004, pages 583A, XP008165785, ISSN: 0270-9139 * |
MALAGUARNERA M ET AL: "Myocardial oxidative stress in an experimental model of nonalcoholic fatty liver disease: role of silibinin", FEBS JOURNAL, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 278, no. Supplement s1, 1 June 2011 (2011-06-01), pages 465, XP008165777, ISSN: 1742-464X, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/doi/10.1111/j.1742-4658.2011.08138.x/pdf> [retrieved on 20110701], DOI: 10.1111/J.1742-4658.2011.08138.X * |
MATTEUCCI ELENA ET AL: "Liver Disease in Diabetes Mellitus: Potential Therapeutic Value of Vitamin E-Silybin Phytosomal Complex", IMMUNOLOGY, ENDOCRINE AND METABOLIC AGENTS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD, NL, vol. 10, no. 2, 1 June 2010 (2010-06-01), pages 84 - 90, XP009170635, ISSN: 1871-5222 * |
SALAMONE FEDERICO ET AL: "Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis", TRANSLATIONAL RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 159, no. 6, 1 June 2012 (2012-06-01), pages 477 - 486, XP008165776, ISSN: 1931-5244, Retrieved from the Internet <URL:http://ac.els-cdn.com/S1931524411004300/1-s2.0-S1931524411004300-main.pdf?_tid=e79e1ea0-486f-11e3-9c9e-00000aacb361&acdnat=1383913301_c13a6082d9d4a2710343785513e37ecc> DOI: 10.1016/J.TRSL.2011.12.003 * |
SATAPATHY S K ET AL: "Novel treatment modalities for nonalcoholic steatohepatitis", TRENDS IN ENDOCRINOLOGY AND METABOLISM, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 21, no. 11, 1 November 2010 (2010-11-01), pages 668 - 675, XP027446389, ISSN: 1043-2760, [retrieved on 20100927], DOI: 10.1016/J.TEM.2010.08.003 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3275457A4 (en) * | 2015-03-23 | 2018-02-21 | Tasly Pharmaceutical Group Co., Ltd. | Pharmaceutical composition containing silybin |
JP2018509429A (en) * | 2015-03-23 | 2018-04-05 | タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドTasly Pharmaceutical Group Co., Ltd. | Combination drug containing silybin |
JP2018509428A (en) * | 2015-03-23 | 2018-04-05 | タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドTasly Pharmaceutical Group Co., Ltd. | Drug composition containing silybin |
US10376490B2 (en) | 2015-03-23 | 2019-08-13 | Tasly Pharmaceutical Group Co., Ltd. | Pharmaceutical composition containing silybin |
RU2700793C2 (en) * | 2015-03-23 | 2019-09-23 | Тасли Фармасьютикал Груп Ко., Лтд. | Pharmaceutical composition containing silybin, vitamin e and l-carnitine |
AU2016236609B2 (en) * | 2015-03-23 | 2021-04-29 | Tasly Pharmaceutical Group Co., Ltd. | Pharmaceutical composition containing silybin |
CN108685899A (en) * | 2017-04-07 | 2018-10-23 | 澳门科技大学 | Flavanolignan is in the application for preparing the drug for treating autoimmune inflammatory diseases |
Also Published As
Publication number | Publication date |
---|---|
EP2976075B1 (en) | 2019-07-17 |
JP2016515540A (en) | 2016-05-30 |
BR112015024181A2 (en) | 2017-07-18 |
RU2694896C2 (en) | 2019-07-18 |
ES2749192T3 (en) | 2020-03-19 |
PT2976075T (en) | 2019-10-14 |
EP2976075A1 (en) | 2016-01-27 |
ITMI20130425A1 (en) | 2014-09-21 |
MX2015013409A (en) | 2016-06-24 |
PL2976075T3 (en) | 2020-03-31 |
HUE045695T2 (en) | 2020-01-28 |
RU2015144870A (en) | 2017-04-25 |
MX370252B (en) | 2019-12-06 |
DK2976075T3 (en) | 2019-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Stiuso et al. | Serum oxidative stress markers and lipidomic profile to detect NASH patients responsive to an antioxidant treatment: a pilot study | |
Choi et al. | Positive effects of astaxanthin on lipid profiles and oxidative stress in overweight subjects | |
Storka et al. | Safety, tolerability and pharmacokinetics of liposomal curcumin (Lipocurc™) in healthy humans | |
Zhang et al. | Dingxin Recipe IV attenuates atherosclerosis by regulating lipid metabolism through LXR-α/SREBP1 pathway and modulating the gut microbiota in ApoE-/-mice fed with HFD | |
Wang et al. | Trillin, a steroidal saponin isolated from the rhizomes of Dioscorea nipponica, exerts protective effects against hyperlipidemia and oxidative stress | |
Ihm et al. | Decaffeinated green tea extract improves hypertension and insulin resistance in a rat model of metabolic syndrome | |
Yang et al. | ATF-2/CREB/IRF-3-targeted anti-inflammatory activity of Korean red ginseng water extract | |
Adachi et al. | Intragastrically administered lysophosphatidic acids protect against gastric ulcer in rats under water-immersion restraint stress | |
RU2699011C2 (en) | Pharmaceutical composition containing silybin and l-carnitine | |
Akase et al. | Preventive effects of Salacia reticulata on obesity and metabolic disorders in TSOD mice | |
Soliman et al. | The ameliorative effect of Petroselinum crispum (parsley) on some diabetes complications | |
Adeneye et al. | Weight losing, antihyperlipidemic and cardioprotective effects of the alkaloid fraction of Hunteria umbellata seed extract on normal and triton-induced hyperlipidemic rats | |
Jia et al. | The anti-atherosclerotic effect of tanshinol borneol ester using fecal metabolomics based on liquid chromatography-mass spectrometry | |
Yao et al. | Hypolipidaemic and antioxidant capacities of polysaccharides obtained from Laminaria japonica by different extraction media in diet‐induced mouse model | |
EP2976075B1 (en) | Silybin for the treatment of metabolic oxidative alterations in patients with non-alcoholic steatohepatitis (nash) | |
Zhao et al. | Protective effects of Scutellaria baicalensis Georgi extract on D-galactose induced aging rats | |
Nimgulkar et al. | Combination of spices and herbal extract restores macrophage foam cell migration and abrogates the athero-inflammatory signalling cascade of atherogenesis | |
Abuelgassim | Lipid Concentrations in Alloxan-induced Diabetic Rats | |
US20090234007A1 (en) | Unsaturated Fatty Acids as Thrombin Inhibitors | |
Mojarradgandoukmolla et al. | Physiological activity and GC-Mass analysis of Trigonella strangulata, Trigonella filipes and Trigonella uncinata against Ethanol-Induced Hepatorenotoxicity in rats | |
Lawson et al. | Effects of Gmelina arborea, Roxb (Verbenaceae) aqueous extract on arterial pressure of Wistar rats | |
EP3197439B1 (en) | Pharmaceutical product, medical food or dietary supplement for preventing cancer and inflammatory diseases | |
Hassan et al. | Study of walnut oil supplementation on serum biochemical parameters and histopathology of male rats | |
JP7467819B2 (en) | Agent for treating, preventing or improving inflammatory and allergic diseases | |
Chang et al. | Integrated 16 S rRNA Gene Sequencing and Serum Metabolomics Approaches to Decipher the Mechanism of Qingre Lidan Decoction in the Treatment of Cholestatic Liver Injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14718921 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016503648 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/013409 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014718921 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015144870 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015024181 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015024181 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150921 |